These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 28412389)

  • 1. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
    Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
    J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
    Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
    Zhang XL; Zhu QQ; Kang LN; Li XL; Xu B
    Ann Intern Med; 2017 Nov; 167(9):642-654. PubMed ID: 29049539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
    Zhang XL; Zhu L; Wei ZH; Zhu QQ; Qiao JZ; Dai Q; Huang W; Li XH; Xie J; Kang LN; Wang L; Xu B
    Ann Intern Med; 2016 Jun; 164(11):752-63. PubMed ID: 27042809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings.
    Seo J; Ahn JM; Hong SJ; Kang DY; Hong SJ; Her AY; Kim YH; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Park DW; Hong MK
    Am J Cardiol; 2020 Jun; 125(11):1624-1630. PubMed ID: 32279841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
    Fam JM; Felix C; van Geuns RJ; Onuma Y; Van Mieghem NM; Karanasos A; van der Sijde J; De Paolis M; Regar E; Valgimigli M; Daemen J; de Jaegere P; Zijlstra F; Diletti R
    EuroIntervention; 2016 May; 12(1):30-7. PubMed ID: 27173859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
    Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
    Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis.
    Toyota T; Morimoto T; Shiomi H; Yoshikawa Y; Yaku H; Yamashita Y; Kimura T
    JACC Cardiovasc Interv; 2017 Jan; 10(1):27-37. PubMed ID: 28057284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.